Nuvalent, Inc.
$107.99
▲
0.8%
2026-04-22 10:12:13
nuvalent.com
NMS: NUVL
Explore Nuvalent, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$8.48 B
Current Price
$107.99
52W High / Low
$113.02 / $63.55
Stock P/E
—
Book Value
$15.96
Dividend Yield
—
ROCE
-31.35%
ROE
-36.7%
Face Value
—
EPS
$-5.85
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
228
Beta
1.31
Debt / Equity
—
Current Ratio
15.27
Quick Ratio
15.27
Forward P/E
-25.46
Price / Sales
—
Enterprise Value
$6.71 B
EV / EBITDA
—
EV / Revenue
—
Rating
Strong Buy
Target Price
$142.39
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Neurogene Inc. | $27.74 | — | $432.03 M | — | -37.96% | -31.41% | $37.27 / $10.46 | $17.1 |
| 2. | GridAI Technologies Corp. | $2.79 | — | $9.38 M | — | -27% | -58.82% | $5.84 / $0.97 | — |
| 3. | Coherus Oncology, Inc. | $1.99 | 1.76 | $295.28 M | — | -155.52% | -473.47% | $2.62 / $0.71 | $0.5 |
| 4. | CytomX Therapeutics, Inc. | $4.89 | — | $1.06 B | — | -21.31% | -35.25% | $8.21 / $0.61 | $0.58 |
| 5. | Agenus Inc. | $4.42 | 1,529.26 | $175.86 M | — | 21.26% | -0.04% | $7.34 / $1.6 | $-7.68 |
| 6. | Apellis Pharmaceuticals, Inc. | $40.94 | 233.76 | $5.23 B | — | 7.37% | 7.48% | $40.95 / $16.1 | $2.92 |
| 7. | Polaryx Therapeutics, Inc. | $5.7 | — | $289.74 M | — | -171.33% | -1.94% | $48.91 / $2.2 | $0.1 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -102.23 M | -112.7 M | -104.57 M | -94.81 M | -86.3 M | — |
| Net Profit | -118.7 M | -122.44 M | -99.65 M | -84.58 M | -74.76 M | — |
| EPS in Rs | -1.62 | -1.67 | -1.36 | -1.16 | -1.02 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -414.31 M | -280.37 M | -149.49 M | -86.11 M |
| Net Profit | -425.38 M | -260.76 M | -126.22 M | -81.85 M |
| EPS in Rs | -5.81 | -3.56 | -1.72 | -1.12 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.41 B | 1.14 B | 732.38 M | 482.46 M |
| Total Liabilities | 164.37 M | 71.96 M | 31.82 M | 19.48 M |
| Equity | 1.25 B | 1.07 B | 700.56 M | 462.98 M |
| Current Assets | 1.39 B | 1.13 B | 726.49 M | 477.99 M |
| Current Liabilities | 91.17 M | 54.02 M | 31.82 M | 19.48 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -275.21 M | -185.06 M | -99.74 M | -64.97 M |
| Investing CF | -124.08 M | -573.51 M | -143.53 M | -10.66 M |
| Financing CF | 515.34 M | 568.88 M | 336.85 M | 248.92 M |
| Free CF | -275.21 M | -185.06 M | -99.74 M | -64.97 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -106.59% | -54.2% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.